“狂飙”和惊天跳水，同现！

Core Viewpoint - The article highlights significant stock market movements in Hong Kong, particularly focusing on the dramatic fluctuations of pharmaceutical companies, including a notable drop in the stock price of Jietian Pharmaceutical and a massive surge in Fosen Pharmaceutical's stock price [12][18]. Market Performance - On September 16, Hong Kong's major stock indices showed mixed results, with the Hang Seng Index down 0.03% at 26,438.51 points, while the Hang Seng Tech Index rose 0.56% to 6,077.66 points. The total market turnover was HKD 294.069 billion, with southbound funds net selling HKD 3.189 billion [2]. - The non-essential consumer sector index rose by 0.38%, the industrial index increased by 0.36%, and the information technology index grew by 0.30%. Conversely, the materials sector index fell by 1.10%, and the healthcare sector index decreased by 1.05% [7]. Company-Specific Movements - Jietian Pharmaceutical experienced a dramatic stock price fluctuation, initially surging by 63.73% after receiving approval for its core product's clinical trial but ultimately closing down 53.73% at HKD 192.00 per share [13][15]. - Fosen Pharmaceutical's stock skyrocketed by 414.71%, closing the day up 367.65% at HKD 1.59 per share after receiving approval for its diabetes medication [18][20]. Sector Analysis - The innovative drug sector is facing differentiation, with market concerns regarding the business development prospects of certain innovative drug companies, particularly due to changes in overseas policies. However, innovative drugs and devices remain focal points for market attention, with larger companies possessing technological platforms being favored [23].